Page 334 - Eshre Final Programme 2015

INDUSTRY SPONSORED SYMPOSIA
Ferring Company Symposium
Monday, 15 June 2015 I Room Lisbon I 11:45 - 13:00
“The ART Spectrum – Where can we make a difference?”
Chairs: Tina Buchholz, Germany & Sérgio Soares, Portugal
11:45 Where can hCG make a difference? - Peter Platteau (Belgium)
12:00 Future concepts: AMH and new gonadotrophins - Juan Garcia-Velasco (Spain)
12:15 Embryo selection and embryology laboratory improvements - Jacques Cohen (U.S.A.) 12:40 Maternal safety and child health after ART - Anja Pinborg (Denmark)
12:55 Close
Merck-Serono Company Symposium
Monday, 15 June 2015 I Room Lisbon I 14:00 - 15:15
As One for Patients: The Quest for the right treatment and laboratory technologies, for the right patient, to maximize success
• Welcome and introduction
• Chairman: José Manuel Sousa Teixeira da Silva (Portugal)
• Defining the most precise and practical biomarker of ovarian response: AFC or AMH - Filippo Ubaldi (Italy)
• Definition, Diagnosis and Treatment of Poor Responders - Peter Humaidan (Denmark)
• Individualization of Laboratory Technologies to maximize success - Natalia Basile (Spain)
Finox Company Symposium
Monday, 15 June 2015 I Room Lisbon I 17:00 - 18:15
“Bemfola - Familiar + More: The first new rhFSH in 18 years, building on the familiar to provide more treatment options”
• Welcome and introductions - Ana Teresa Moreira Almeida Santos and Klaus Diedrich
• Finox Biotech: Familiar + More, our commitment to fertility now and in the future - Gavin Jelic-Masterton, CEO Finox Biotech
• Developing a new biologic rhFSH (Bemfola) based on a reference product: what it is and what it is not - Fernando de Mora
• 18 years on: How technological advances have enabled the creation and precise characterization of Bemfola; a new follitropin alfa - Scott Chappel
• Bemfola in clinical practice - and why less can really be more - Julian Jenkins
• Meeting close - Ana Teresa Moreira Almeida Santos and Klaus Diedrich
334